Principal Advisors

Industries

Offices

Antisoma licenses rights to develop Betagenon's AMPK activators as cancer treatments

Client

Antisoma plc

Date

April 2008
On April 14, 2008, Cancer drug developer Antisoma plc acquired a licence from Betagenon AB, a privately held Swedish biotechnology company, to develop and commercialise Betagenon's AMPK activators in cancer indications.

Antisoma was advised by Gary Howes of Fasken Martineau Stringer Saul.